Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 209936
Company: BAYER HEALTHCARE
Company: BAYER HEALTHCARE
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
ALIQOPA | COPANLISIB DIHYDROCHLORIDE | 60MG/VIAL | POWDER;INTRAVENOUS | Discontinued | None | Yes | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
09/14/2017 | ORIG-1 | Approval | Type 1 - New Molecular Entity | PRIORITY; Orphan |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209936Orig1s000Ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209936Orig1_toc.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
09/07/2023 | SUPPL-12 | Labeling-Package Insert, Labeling-Patient Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209936s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209936Orig1s012ltr.pdf | |
03/30/2023 | SUPPL-11 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209936s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209936Orig1s011ltr.pdf | |
02/23/2022 | SUPPL-10 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209936s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209936Orig1s010ltr.pdf | |
05/17/2021 | SUPPL-6 | Labeling-Package Insert |
Label is not available on this site. |
||
02/12/2020 | SUPPL-4 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209936s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209936Orig1s004ltr.pdf | |
10/28/2019 | SUPPL-3 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209936s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209936Orig1s003ltr.pdf | |
05/24/2019 | SUPPL-2 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209936s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209936Orig1s002ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
09/07/2023 | SUPPL-12 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209936s012lbl.pdf | |
09/07/2023 | SUPPL-12 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209936s012lbl.pdf | |
03/30/2023 | SUPPL-11 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209936s011lbl.pdf | |
02/23/2022 | SUPPL-10 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209936s010lbl.pdf | |
02/12/2020 | SUPPL-4 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209936s004lbl.pdf | |
10/28/2019 | SUPPL-3 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209936s003lbl.pdf | |
05/24/2019 | SUPPL-2 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209936s002lbl.pdf | |
09/14/2017 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf |